Xenical (Orlistat) Anti-Obesity Agent 120mg Capsules 21s with FREE Tote Bag - Keimav

Xenical (Orlistat) Anti-Obesity Agent 120mg Capsules - 21s with FREE Tote BagBrand Name - XenicalGeneric Name - OrlistatStrength - 120mgDosage Form - CapsuleClass Name - Anti-Obesity AgentsIndication/Usage - In conjunction w/ a mildly hypocaloric diet, treatment of obese or overwt patients w/ associated comorbidities.Dosage and Administration - 1 cap w/ each main meal. Should be taken with food: Take immediately before or during or up to 1 hr after each main meal. If a meal is missed or contains no fat, the dose may be omitted.Contraindications - Hypersensitivity. Chronic malabsorption syndrome, cholestasis.Warning and Precautions - Monitor cyclosporine plasma levels when co-administered w/ Xenical. Patients treated w/ concomitant oral anticoagulants. Intake of amiodarone. Pregnancy & lactation. Children below 12 years old.Requires prescription? - NoStorage Conditions - Do not store above 25°C. Store in original package and keep the blister in the outer carton, in order to protect from light and moisture.Regulatory Classification - Non-RxLATEST, FRESHEST & NEWEST STOCKS! ONLY FROM OUR STORE!Expiration: June 2027 and onwardsProduct details ofXenical (Orlistat) Anti-Obesity Agent 120mg Capsules - 21s with FREE Tote BagXENICAL is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia).Important Safety InformationXENICAL is contraindicated in patients:who are pregnant. Weight loss offers no potential benefit to a pregnant woman and may result in fetal harm. A minimum weight gain, and no weight loss, is currently recommended for all pregnant women, including those who are already overweight or obese, due to the obligatory weight gain that occurs in maternal tissues during pregnancywith chronic malabsorption syndromewith cholestasiswith known hypersensitivity to XENICAL or to any component of this productWarnings and Precautions:XENICAL may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugsXENICAL can decrease cyclosporine exposure. XENICAL and cyclosporine should not be simultaneously co-administeredPatients should be strongly encouraged to take a multivitamin supplement that contains fat-soluble vitamins to ensure adequate nutrition because XENICAL has been shown to reduce the absorption of some fat-soluble vitamins and beta-caroteneRare cases of severe liver injury with hepatocellular necrosis or acute hepatic failure have been reported, with some of these cases resulting in liver transplant or deathPatients may develop increased levels of urinary oxalate following treatment with XENICAL. Monitor renal function in patients at risk for renal insufficiency.Substantial weight loss can increase the risk of cholelithiasisExclude organic causes of obesity (e.g., hypothyroidism) before prescribing XENICALPatients should be advised to adhere to dietary guidelines. Gastrointestinal events may increase when XENICAL is taken with a diet high in fat (>30% total daily calories from fat)It is not known if XENICAL is present in human milk. Caution should be exercised when XENICAL is administered to a nursing woman.The most commonly observed adverse events (incidence of ≥5% and twice that of placebo) were oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation and fecal incontinence. In general, the first occurrence of these events was within 3 months of starting therapy.Overall, approximately 50% of all episodes of GI adverse events associated with XENICAL treatment lasted for less than 1 week, and a majority lasted for no more than 4 weeks. However, GI adverse events may occur in some individuals over a period of 6 months or longer.Expiration: June 2027